These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24725485)

  • 41. Prostate cancer and the increasing role of active surveillance.
    Alonzo DG; Mure AL; Soloway MS
    Postgrad Med; 2013 Sep; 125(5):109-16. PubMed ID: 24113669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate cancer screening; is this a teachable moment?
    Brawley OW
    J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
    [No Abstract]   [Full Text] [Related]  

  • 45. Should prostate-specific antigen screening be offered to asymptomatic men?
    van Vugt HA; Bangma CH; Roobol MJ
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Active surveillance for screen-detected prostate cancer - a strategy for the future?].
    Weissbach L; Schaefer C
    Aktuelle Urol; 2010 Jul; 41(4):239-44. PubMed ID: 20661840
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Case for Tailored Prostate Cancer Screening: An NCCN Perspective.
    McDonald ML; Parsons JK
    J Natl Compr Canc Netw; 2015 Dec; 13(12):1576-83. PubMed ID: 26656524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A practical guide to prostate cancer diagnosis and management.
    Simmons MN; Berglund RK; Jones JS
    Cleve Clin J Med; 2011 May; 78(5):321-31. PubMed ID: 21536828
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [What has changed in the epidemiology and screening of prostate cancer?].
    Portela-Pereira P; Gómez-Veiga F
    Arch Esp Urol; 2015 Apr; 68(3):202-9. PubMed ID: 25948794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate cancer: Prudent practice optimizes screening outcomes.
    Auvinen A
    Nat Rev Urol; 2016 Jul; 13(7):376-7. PubMed ID: 27215425
    [No Abstract]   [Full Text] [Related]  

  • 53. [Early detection or screening in the prevention of prostate cancer?].
    Brenes Bermúdez FJ; Alcántara Montero A
    Semergen; 2017 Mar; 43(2):100-108. PubMed ID: 26960257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not?
    Downer MK; Stampfer MJ; Cooperberg MR
    JAMA Oncol; 2017 Dec; 3(12):1623-1624. PubMed ID: 28494051
    [No Abstract]   [Full Text] [Related]  

  • 55. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries.
    Ross JS; Wang R; Long JB; Gross CP; Ma X
    Arch Intern Med; 2012 Nov; 172(20):1601-3. PubMed ID: 22987029
    [No Abstract]   [Full Text] [Related]  

  • 56. Off the mark: Current lung cancer screening guidelines miss those most at risk.
    Printz C
    Cancer; 2015 Aug; 121(15):2477-8. PubMed ID: 26198788
    [No Abstract]   [Full Text] [Related]  

  • 57. Screening for prostate cancer: early detection or overdetection?
    Vickers AJ; Roobol MJ; Lilja H
    Annu Rev Med; 2012; 63():161-70. PubMed ID: 22053739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Making the grade: The newest US Preventive Services Task Force prostate cancer screening recommendation.
    Hoffman RM; Volk RJ; Wolf AMD
    Cancer; 2017 Oct; 123(20):3875-3878. PubMed ID: 28832967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.
    Carroll PR; Parsons JK; Andriole G; Bahnson RR; Barocas DA; Castle EP; Catalona WJ; Dahl DM; Davis JW; Epstein JI; Etzioni RB; Farrington T; Hemstreet GP; Kawachi MH; Lange PH; Loughlin KR; Lowrance W; Maroni P; Mohler J; Morgan TM; Nadler RB; Poch M; Scales C; Shaneyfelt TM; Smaldone MC; Sonn G; Sprenke P; Vickers AJ; Wake R; Shead DA; Freedman-Cass D
    J Natl Compr Canc Netw; 2015 Dec; 13(12):1534-61. PubMed ID: 26656522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Overdiagnosis in prostate cancer].
    Villeda C; Gomez MO; Sotomayor M
    Arch Esp Urol; 2014 Jun; 67(5):388-92. PubMed ID: 24914837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.